Publications and Digital Products

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.

This pamphlet offers reasons to combine tobacco cessation and substance use disorder treatment, including client testimonials and resources for implementing a tobacco cessation program. It also explains the benefits of offering tobacco cessation programs in substance use disorder treatment settings.

Equipa a los proveedores de atención médica, las comunidades y los gobiernos locales con materiales para desarrollar prácticas y políticas para ayudar a prevenir las sobredosis y las muertes relacionadas con los opioides. Aborda diferentes asuntos de interés para los proveedores de atención médica, personal de primeros auxilios, los proveedores de tratamientos y los que están recuperándose de sobredosis de opioides. Actualizada en el 2018.

This guide offers best practices for treating women living with substance use disorders in co-ed treatment and recovery settings. It highlights the importance of gender differences, cultural sensitivity, and developing healthy relationships.

This manual serves as a quick reference guide for clinicians treating chronic pain in adults living with a history of substance use. It covers patient assessment and treatment, and provides an algorithm for managing chronic pain, as well as a summary of non-opioid analgesics.

This manual provides physicians with quick reference information about three FDA-approved medications to help patients achieve abstinence from alcohol: acamprosate, disulfiram, and naltrexone (oral and extended-release). It also includes patient management tips.

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.